Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM L COOPER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1477512663
CMS profile
112549
Location
THOMASVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$270.39

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $270.39 15

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $73.75 5
ABBVIE INC. $61.82 3
Novartis Pharmaceuticals Corporation $43.84 2
Janssen Pharmaceuticals, Inc $32.64 2
Incyte Corporation $23.24 1
Novo Nordisk Inc $17.73 1
GlaxoSmithKline, LLC. $17.37 1

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM L COOPER

NPI 1477512663 · CMS profile ID 112549

Allopathic & Osteopathic Physicians / Internal Medicine

THOMASVILLE, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477512663?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM L COOPER, NPI 1477512663, CMS profile ID 112549. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477512663?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). WILLIAM L COOPER, NPI 1477512663, CMS profile ID 112549. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477512663?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
WILLIAM L COOPER, NPI 1477512663, CMS profile ID 112549, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1477512663?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $270.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.1411/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949544495 CMS
GlaxoSmithKline, LLC. $17.3710/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944612610 CMS
Novo Nordisk Inc $17.7310/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899110513 CMS
PFIZER INC. $16.0509/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949381613 CMS
Janssen Pharmaceuticals, Inc $16.3207/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886100633 CMS
Novartis Pharmaceuticals Corporation $23.8406/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893582279 CMS
PFIZER INC. $14.9006/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949373815 CMS
Novartis Pharmaceuticals Corporation $20.0005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893582277 CMS
Janssen Pharmaceuticals, Inc $16.3204/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886100627 CMS
ABBVIE INC. $15.2704/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890794243 CMS
PFIZER INC. $12.6103/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949377843 CMS
ABBVIE INC. $25.4802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890794241 CMS
Incyte Corporation $23.2402/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942913695 CMS
PFIZER INC. $16.0501/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949399771 CMS
ABBVIE INC. $21.0701/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890794239 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $406.91 26
PY2020 $75.26 4
PY2021 $192.75 12
PY2022 $270.39 15
PY2023 $296.07 18
PY2024 $151.20 8
PY2025 $208.17 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $431,894.86 49
PY2024 Principal investigator $232,854.48 6
PY2023 Principal investigator $288,970.92 7
PY2022 Principal investigator $75,589.14 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $32.39 12/31/2025 Non-covered Recipient Entity
MCINTOSH CLINIC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190304515
Principal investigator 1 Genentech, Inc. $3,474.00 12/19/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618097
Principal investigator 1 Genentech, Inc. $481.00 12/19/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618147
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/18/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998667
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 12/17/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774411
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774413
Principal investigator 1 Genentech, Inc. $9,467.00 12/04/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618101
Principal investigator 1 Genentech, Inc. $3,500.00 12/04/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618137
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774405
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 11/11/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998665
Principal investigator 1 Genentech, Inc. $2,661.00 11/07/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618030
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774403
Principal investigator 1 Genentech, Inc. $6,076.00 10/29/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617959
Principal investigator 1 Genentech, Inc. $962.00 10/29/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211618005
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774407
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774409
Principal investigator 1 Genentech, Inc. $2,564.00 10/23/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617952
Principal investigator 1 Genentech, Inc. $3,451.00 10/16/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617935
Principal investigator 1 Genentech, Inc. $1,774.00 10/09/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617970
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,045.57 10/08/2025 Non-covered Recipient Entity
MCINTOSH CLINIC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190304519
Principal investigator 1 Genentech, Inc. $4,003.00 10/03/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617974
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774401
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/23/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998663
Principal investigator 1 Genentech, Inc. $3,116.00 09/23/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617897
Principal investigator 1 Genentech, Inc. $11,118.00 09/18/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617889
Principal investigator 1 Genentech, Inc. $1,192.00 09/18/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617893
Principal investigator 1 Genentech, Inc. $2,900.00 09/18/2025 Non-covered Recipient Entity
JAVARA INC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211617901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,200.00 09/12/2025 Non-covered Recipient Entity
Javara Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220801888
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774395
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774397
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774399
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 08/18/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815680
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774393
Principal investigator 1 Novartis Pharmaceuticals Corporation $42,794.05 07/08/2025 Non-covered Recipient Entity
JAVARA, INC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190310699
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 07/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774385
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 07/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774387
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774389
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 07/01/2025 Non-covered Recipient Entity
Mcintosh Clinic-Thomasville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220774391
Principal investigator 1 Medtronic, Inc. $366.00 04/25/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327640
Principal investigator 1 Medtronic, Inc. $5,000.00 04/25/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327642
Principal investigator 1 Medtronic, Inc. $4,671.00 04/25/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327644
Principal investigator 1 Medtronic, Inc. $525.00 04/25/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327646
Principal investigator 1 Novartis Pharmaceuticals Corporation $43,725.11 03/24/2025 Non-covered Recipient Entity
MCINTOSH CLINIC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190304517
Principal investigator 1 Novartis Pharmaceuticals Corporation $106,559.82 03/05/2025 Non-covered Recipient Entity
MCINTOSH CLINIC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190304521
Principal investigator 1 Medtronic, Inc. $202.00 02/21/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327638
Principal investigator 1 Medtronic, Inc. $1,063.00 01/31/2025 Non-covered Recipient Entity
Javara Inc.
CIP341 IMPACT2 No dispute reported 06/30/2026 1192327636
Principal investigator 1 Novartis Pharmaceuticals Corporation $85,792.99 01/27/2025 Non-covered Recipient Entity
JAVARA RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312191
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,197.60 01/07/2025 Non-covered Recipient Entity
JAVARA, INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310685
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,378.80 01/07/2025 Non-covered Recipient Entity
JAVARA, INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310689